Lipoprotein(a) Screening Guidelines

Introduction to Lipoprotein(a) Screening

• The American College of Cardiology recommends selective measurement of lipoprotein(a) in specific high-risk populations based on established cardiovascular risk factors and clinical scenarios, rather than routine screening for all individuals 1

Standard Lipid Screening Components

• Total cholesterol and HDL cholesterol are the recommended components of routine lipid screening, not lipoprotein(a), according to the American Academy of Family Physicians 2, 3, 4
• LDL cholesterol and triglycerides provide additional information but require fasting samples and are more expensive, with triglyceride measurement having insufficient evidence for routine screening 2, 5

Specific Indications for Lipoprotein(a) Testing

• Patients with premature cardiovascular disease or stroke should have lipoprotein(a) measured, especially when traditional risk factors don't fully explain the disease, as recommended by the American College of Cardiology 1
• Family history of premature CAD, particularly first-degree relatives with premature atherosclerotic CVD or Lp(a) levels >200 nmol/L, is an indication for lipoprotein(a) testing 1
• All patients with familial hypercholesterolemia or other genetic dyslipidemia should have Lp(a) measured, as elevated Lp(a) and LDL cholesterol together confer a 10-fold or higher risk of myocardial infarction, according to the American College of Cardiology 1
• Intermediate cardiovascular risk by standard calculators, such as the Framingham or ESC Heart Score, may justify lipoprotein(a) testing, as Lp(a) levels >50 mg/dL may reclassify individuals into a higher risk category 1

Clinical Rationale for Selective Screening

• The American College of Cardiology Foundation/American Heart Association guidelines found continuous, independent associations of Lp(a) with increased risk for CHD and stroke based on 36 prospective studies involving >125,000 participants 1

Management Implications When Elevated Lp(a) Is Identified

• Intensive treatment of traditional modifiable risk factors, especially LDL cholesterol, is justified by the additional risk conferred by elevated Lp(a), with lower LDL-C goals, as recommended by the American College of Cardiology 1

Common Pitfalls to Avoid

• The American Academy of Family Physicians recommends against ordering Lp(a) testing universally for all patients undergoing routine lipid screening, as this is not supported by current guidelines and is not cost-effective 2, 1
• The American College of Cardiology advises against relying on a single Lp(a) measurement for major treatment decisions without confirming the result, though Lp(a) levels generally remain stable over time 6, 1